Table 5Treatment efficacy and safety

Author, YearExperimental Drug vs. ControlMedian PFS (Experimental vs. Control)PFS, Experimental vs. Control HR (95% CI)Median OS (Experimental vs. Control)OS, Experimental vs. Control HR (95% CI)ORR, Experimental vs. Control % (95% CI)Any Grade 3/4 Adverse Events in Experimental Group N (%)Any Grade 3/4 Adverse Events in Control Group N (%)
Cella, 201262pazopanib vs. placebo9.2 vs. 4.2 mos0.46 (0.34–0.62), p< 0.0001NRNR (data not mature)30 vs. 3, p< 0.00140%20%
Sherrill, 201063letrozole + lapatinib vs. letrozole + placebo8.2 vs. 3 mos0.71 (0.53–0.96), p= 0.01933.3 vs. 32.3 mos0.74 (0.5–1.1), p= 0.11328 vs. 15, p= 0.021diarrhea 10%; rash 1%diarrhea 1%; rash 0%
Siena, 200764panitumumab + BSC vs. BSC alone8 wks vs. 7.3 (mean 13.8 wks vs. 8.5)0.54 (0.44–0.66), p<0.0001NR1.0 (82–1.22), p= 0.8110 vs. 0 (at 1 yr)of 229, 79 (35)of 234, 45 (20)
Zhou, 200961lapatinib + capecitabine vs. capecitabine aloneNR0.55 (0.4–0.74), p< 0.00115.6 vs. 15.3 mos0.78 (0.55–1.12), p= 0.17724 vs. 14, p= 0.01735%33%

BSC = best supportive care; CI = confidence interval; HR = hazard ratio; Mo(s) = months; NR = not reported; ORR = objective response rate; P = probability; PFS = progression-free survival; OS = overall survival; Wks = weeks

From: Results

Cover of Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life?
Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? [Internet]
Gutman SI, Piper M, Grant MD, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.